Wednesday, October 25, 2017

=Cellect Biotechnology (APOP) : major breakthrough of ApoGraft technology




  • Positive Results from a 20 Patients Trial With Tel-Aviv Ichilov Medical Center

Cellect Biotechnology announces conclusion of study on the use ApoGraft on stem cells derived from fat tissues 
Co states, "The significance of the findings opens ApoGraft to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments. Of special importance are the aesthetic and orthopedic indications where fat-derived stem cells are the main raw material."

No comments:

Post a Comment